{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T05:24:34Z","timestamp":1791955474817,"version":"4.3.4"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T00:00:00Z","timestamp":1590624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Limited options exist for treating post-recurrence patients with malignant pleural mesothelioma (MPM). This study aimed to evaluate the efficacy and feasibility of nivolumab in patients with post-operative recurrence of MPM in a real-world setting.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study included 35 patients with post-operative recurrence of MPM. Treatment consisted of 240-mg intravenous nivolumab administration every 2\u00a0weeks until progressive disease (PD) or serious adverse events (AEs). Additional post-treatment data were evaluated, including objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), post-treatment survival and AEs. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors. Survival analysis was performed using the Kaplan\u2013Meier method. The feasibility analysis including AEs was performed with the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of the 35 patients who received nivolumab, median follow-up was 6\u00a0months. The median treatment duration was 3\u00a0months (range: 1\u201314\u00a0months), and median of 8 cycles (range: 2\u201332\u00a0cycles) was administered. Best overall responses were follows: 1 patient had complete response, 6 had partial response, 18 had stable disease and 8 had PD. The ORR was 20.0%, and the DCR was 77.1%. The median overall survival and PFS were 13.1 and 4.4\u00a0months, respectively. There were grade-3 AEs in four patients (11.4%). No grade-4 or -5 AEs were observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Nivolumab treatment in patients with post-operative recurrence of MPM seems safe and clinical efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jjco\/hyaa069","type":"journal-article","created":{"date-parts":[[2020,4,29]],"date-time":"2020-04-29T11:18:25Z","timestamp":1588159105000},"page":"920-925","source":"Crossref","is-referenced-by-count":12,"title":["Initial evaluation of nivolumab in patients with post-operative recurrence of malignant pleural mesothelioma"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5742-9527","authenticated-orcid":false,"given":"Akifumi","family":"Nakamura","sequence":"first","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Kondo","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Nakamichi","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Kuroda","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yokoi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Thoracic Oncology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Kuribayashi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kijima","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Department of Internal Medicine, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiki","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Division of Thoracic Surgery, Department of Surgery, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,5,28]]},"reference":[{"key":"2020080408103518200_ref1","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.jtcvs.2014.10.128","article-title":"Updated patterns of failure after multimodality therapy for malignant pleural mesothelioma","volume":"149","author":"Baldini","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2020080408103518200_ref2","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00520-017-3666-z","article-title":"Physical function and health-related quality of life in patients undergoing surgical treatment for malignant pleural mesothelioma","volume":"25","author":"Tanaka","year":"2017","journal-title":"Support Care Cancer"},{"key":"2020080408103518200_ref3","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"2020080408103518200_ref4","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2020080408103518200_ref5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1053\/j.semtcvs.2019.01.010","article-title":"Surgical risk and survival associated with less invasive surgery for malignant pleural mesothelioma","volume":"31","author":"Hasegawa","year":"2019","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"2020080408103518200_ref6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtcvs.2018.09.106","article-title":"Pleural thickness after neoadjuvant chemotherapy is a prognostic factor in malignant pleural mesothelioma","volume":"157","author":"Hashimoto","year":"2019","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2020080408103518200_ref7","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/j.athoracsur.2019.11.048","article-title":"Clinical outcomes with recurrence after pleurectomy\/decortication for malignant pleural mesothelioma","volume":"109","author":"Nakamura","year":"2020","journal-title":"Ann Thorac Surg"},{"key":"2020080408103518200_ref8","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"2020080408103518200_ref9","author":"National Cancer Institute [Internet]. Maryland: Common Terminology Criteria for Adverse Events, version 5.0 (CTCAEv5.0). [cited Feb 15, 2020]"},{"key":"2020080408103518200_ref10","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10147-017-1126-x","article-title":"Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy","volume":"22","author":"Takuwa","year":"2017","journal-title":"Int J Clin Oncol"},{"key":"2020080408103518200_ref11","doi-asserted-by":"crossref","first-page":"5438","DOI":"10.1158\/1078-0432.CCR-19-1836","article-title":"Nivo-lution in mesothelioma","volume":"25","author":"Mansfield","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2020080408103518200_ref12","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"2020080408103518200_ref13","doi-asserted-by":"crossref","first-page":"243","DOI":"10.21037\/atm.2017.06.26","article-title":"Malignant pleural mesothelioma: predictors and staging","volume":"5","author":"Richards","year":"2017","journal-title":"Ann Transl Med"},{"key":"2020080408103518200_ref14","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/00016489.2019.1648867","article-title":"Efficacy and safety of nivolumab in 100 patients with recurrent or metastatic head and neck cancer \u2013 a retrospective multicentre study","volume":"139","author":"Okamoto","year":"2019","journal-title":"Acta Otolaryngol"}],"container-title":["Japanese Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/8\/920\/33563545\/hyaa069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jjco\/article-pdf\/50\/8\/920\/33563545\/hyaa069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T12:11:31Z","timestamp":1596543091000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jjco\/article\/50\/8\/920\/5848077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,28]]},"references-count":14,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2020,5,28]]},"published-print":{"date-parts":[[2020,8,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jjco\/hyaa069","relation":{},"ISSN":["1465-3621"],"issn-type":[{"value":"1465-3621","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8]]},"published":{"date-parts":[[2020,5,28]]}}}